BIO-Europe Spring 2019: Virion CEO outlines plans for first broad-spectrum respiratory antiviral скачать в хорошем качестве

BIO-Europe Spring 2019: Virion CEO outlines plans for first broad-spectrum respiratory antiviral

https://ebdgroup.knect365.com/bioeuro... Today, the vast majority of respiratory viruses are not addressable with either vaccines or treatments. Virion Biotherapeutics is aiming to change that, using scientific knowledge developed at the University of Warwick. CEO Vanessa King spoke to Scrip at BIO-Europe Spring 2019. Virion Biotherapeutics is a preclinical-stage company focused on taking a novel RNA treatment modality into the clinic. Its technology involves packaging a piece of RNA into an inactive influenza virus for inhaled delivery into the lung to treat viruses locally. The aim is to stimulate the innate immune response locally to achieve broad-spectrum anti-viral treatment for respiratory viruses including flu, RSV or rhinovirus. King points out that with 85% of respiratory viruses currently not addressed by either prophylactic or therapeutic treatments, there is significant unmet need in this space. Founded in 2017, the UK firm hopes to have a product in human clinical trials by 2021. The company is planning a “pretty hefty” series B fundraising in 2019, which will also help it expand its platform and/or therapeutic focus.